COVIDomics_plasma_2020_DDA-PASEF

In order to investigate variations in the endotype of COVID19 patients, we completed an integrated analysis of 112 research participants, including 74 COVID19 patients versus 37 SARS-CoV-2 negative controls. COVID19 patients tested positive for SARS-CoV-2 infection by PCR and/or antibody testing and were hospitalized due to COVID19 symptoms, but none of them had developed severe pathology requiring ICU admission at the time of blood collection. The control group was recruited from the same hospital system but tested negative for SARS-CoV-2 infection. Research blood draws were obtained from consented participants and analyzed by matched SARS-CoV-2 seroconversion assays, plasma proteomics using two alternative platforms [mass-spectrometry (MS), and SOMAscan assays], 82-plex cytokine profiling using Meso Scale Discovery (MSD) assays, and immune cell profiling via mass cytometry (MC).为探究新型冠状病毒肺炎（COVID19）患者的内型（endotype）变异，本研究完成了对112名研究受试者的整合分析，其中包含74名COVID19患者与37名严重急性呼吸综合征冠状病毒2（SARS-CoV-2）阴性对照者。COVID19患者经聚合酶链式反应（PCR）和/或抗体检测确认SARS-CoV-2感染阳性，且因COVID19相关症状住院治疗，但采血时均未出现需重症监护室（ICU）收治的重症病症。对照组从同一医院系统招募，其SARS-CoV-2感染检测结果为阴性。本研究从签署知情同意书的受试者处采集研究用血液样本，并开展了如下分析：匹配的SARS-CoV-2血清转换检测、采用两种不同平台的血浆蛋白质组学分析[质谱（mass-spectrometry, MS）与SOMAscan检测]、采用Meso Scale Discovery（MSD）检测的82重细胞因子谱分析，以及通过质谱流式细胞术（mass cytometry, MC）开展的免疫细胞谱分析。